Lantheus (LNTH) Q3 2026 Earnings
Adjusted EPS excludes a $31.0 million impairment of intangible assets, $46.9 million of acquisition, integration and divestiture-related items, a $12.2 million net loss on investment in equity securities, $21.9 million of stock and incentive plan compensation and $16.7 million of amortization of acquired intangibles; GAAP diluted EPS was $0.33.
How Did LNTH Stock React to Q3 2026 Earnings?
Did LNTH Beat Earnings? Q3 2026 Results
Yes. Lantheus reported Q3 2026 earnings of $1.68 a share on Nov 5, 2026, beating the $1.26 consensus estimate by 33.2%. Revenue was $389.9M against a $356.7M estimate.
Lantheus Holdings delivered a sharp earnings beat in the third quarter of 2026, posting adjusted EPS of $1.68 against a consensus estimate of $1.26, a 33.19% beat that extended the company's streak of topping Wall Street's EPS forecasts to four consecutive quarters. Revenue reached $389.91 million, ahead of the $356.70 million consensus by 9.31% and up 1.5% year over year, even as the year-ago period included $27.47 million of SPECT revenue that did not recur following a divestiture. The adjusted results were driven by strong execution across the portfolio, with Neuraceq nearly tripling to $45.58 million and DEFINITY climbing 4.8% to $85.67 million, partially offsetting a modest 0.7% dip in flagship PYLARIFY to $238.93 million. Adjusted operating income rose 28.1% to $153.20 million, lifting adjusted operating margin to 39.3%. The quarter unfolded under the looming shadow of Curium's pending $103-per-share cash acquisition, a deal that led Lantheus to suspend its full-year 2026 guidance; with FTC review still active and other approvals outstanding, investors are left without formal financial targets as the transaction works through regulatory channels.
- Neuraceq sales up 123.0% to $45.6 million
- DEFINITY sales up 4.8% to $85.7 million
- Strategic partnerships and other revenue up 44.0%
- PYLARIFY sales down 0.7% to $238.9 million
- Absence of SPECT revenue ($27.5 million in the prior-year quarter) following divestiture
- R&D expense rose to $92.8 million from $48.0 million
- $31.0 million intangible asset impairment and $46.9 million of acquisition, integration and divestiture-related items weighed on GAAP results
- Adjusted operating margin expanded to 39.3% from 31.1%
What Is Lantheus's Outlook?
Lantheus suspended its previously issued full-year 2026 financial guidance in connection with the pending merger with Curium and did not host a conference call. Completion of the deal remains subject to closing conditions, including expiration or termination of the HSR waiting period (extended by the FTC on October 21, 2026) and other antitrust and foreign direct investment approvals.
LNTH YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $389.9M | $384.0M | +1.5% |
| Gross Profit | $243.4M | $222.4M | +9.5% |
| Operating Income | $32.2M | $43.6M | −26.2% |
| Net Income | $22.4M | $27.8M | −19.4% |
LNTH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.